Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shenzhen Chipscreen Biosciences Co., Ltd.

http://www.chipscreen.com

Latest From Shenzhen Chipscreen Biosciences Co., Ltd.

Chinese Biotechs Step Onto World Stage With Innovative Products, Competitive Prices

In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.

China Business Strategies

Two Years On, China’s STAR Attracts Star Players But With New Hurdles

Created to take on Nasdaq in the US, the Shanghai Stock Exchange’s STAR Market is celebrating its two-year anniversary with star performers such as CanSino. But its viability as an alternative will be tested by BeiGene, which is set to start trading in Shanghai following dual listings in New York and Hong Kong, with the latter continuing to attract other biopharma IPOs.

China Financing

Lessons Learned And What's Ahead: I-Mab, JW, RemeGen CEOs On Biotech Financing

Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.

China Financing
See All

Company Information

UsernamePublicRestriction

Register